Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 114.42M |
| Revenue (ttm) | 319,591 |
| Net Income (ttm) | -17.99M |
| Shares Out | 22.86M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,856,175 |
| Open | 4.95 |
| Previous Close | 4.86 |
| Day's Range | 4.71 - 5.25 |
| 52-Week Range | 3.13 - 8.40 |
| Beta | 6.54 |
| Analysts | Buy |
| Price Target | 10.50 (+109.2%) |
| Est. Earnings Date | Nov 11, 2021 |
About CAPR
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials in...
Financial Performance
In 2020, CAPR's revenue was $310,250, a decrease of -69.13% compared to the previous year's $1.01 million. Losses were -$13.66 million, 78.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is 10.50, which is an increase of 109.16% from the latest price.
News
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular ...
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 -
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World M...
-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- -Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Pre...
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, ...
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET
Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy...
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based the...
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...
Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extrace...
-Capricor's Findings Support Expansion Across Multiple Therapeutic Targets-
Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
---Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy-
Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET
Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact
Capricor Therapeutics (NASDAQ: CAPR) has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of th...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes-
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles-
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
-Technology Licensed from Johns Hopkins University-
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duc...
—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, t...
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
- Data Expected Second Quarter 2021 -
Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript
Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins - -Deve...
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET